RYTM Cash-Secured Put Strategy
RYTM (Rhythm Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome.
RYTM (Rhythm Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $7.53B, a beta of 1.92 versus the broader market, a 52-week range of 62.29-122.2, average daily share volume of 815K, a public-listing history dating back to 2017, approximately 283 full-time employees. These structural characteristics shape how RYTM stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.92 indicates RYTM has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a cash-secured put on RYTM?
A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike.
Current RYTM snapshot
As of June 29, 2026, spot at $108.78, ATM IV 55.00%, IV rank 15.91%, expected move 15.77%. The cash-secured put on RYTM below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this cash-secured put structure on RYTM specifically: RYTM IV at 55.00% is on the cheap side of its 1-year range, which means a premium-selling RYTM cash-secured put collects less credit per unit of strike-width risk, with a market-implied 1-standard-deviation move of approximately 15.77% (roughly $17.15 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RYTM expiries trade a higher absolute premium for lower per-day decay. Position sizing on RYTM should anchor to the underlying notional of $108.78 per share and to the trader's directional view on RYTM stock.
RYTM cash-secured put setup
The RYTM cash-secured put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RYTM near $108.78, the first option leg uses a $105.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RYTM chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RYTM shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Sell 1 | Put | $105.00 | $3.43 |
RYTM cash-secured put risk and reward
- Net Premium / Debit
- +$342.50
- Max Profit (per contract)
- $342.50
- Max Loss (per contract)
- -$10,156.50
- Breakeven(s)
- $101.58
- Risk / Reward Ratio
- 0.034
Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium.
RYTM cash-secured put payoff curve
Modeled P&L at expiration across a range of underlying prices for the cash-secured put on RYTM. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$10,156.50 |
| $24.06 | -77.9% | -$7,751.42 |
| $48.11 | -55.8% | -$5,346.35 |
| $72.16 | -33.7% | -$2,941.27 |
| $96.21 | -11.6% | -$536.20 |
| $120.26 | +10.6% | +$342.50 |
| $144.31 | +32.7% | +$342.50 |
| $168.37 | +54.8% | +$342.50 |
| $192.42 | +76.9% | +$342.50 |
| $216.47 | +99.0% | +$342.50 |
When traders use cash-secured put on RYTM
Cash-secured puts on RYTM earn premium while a trader waits to acquire RYTM stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning RYTM.
RYTM thesis for this cash-secured put
The market-implied 1-standard-deviation range for RYTM extends from approximately $91.63 on the downside to $125.93 on the upside. A RYTM cash-secured put lets a trader earn premium while waiting to acquire RYTM at the strike price; the strategy is most attractive when the trader is comfortable holding the underlying at that level and IV is rich enough to compensate for the assignment risk. Current RYTM IV rank near 15.91% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RYTM at 55.00%. As a Healthcare name, RYTM options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RYTM-specific events.
RYTM cash-secured put positions are structurally neutral to slightly bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RYTM positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RYTM alongside the broader basket even when RYTM-specific fundamentals are unchanged. Short-premium structures like a cash-secured put on RYTM carry tail risk when realized volatility exceeds the implied move; review historical RYTM earnings reactions and macro stress periods before sizing. Always rebuild the position from current RYTM chain quotes before placing a trade.
Frequently asked questions
- What is a cash-secured put on RYTM?
- A cash-secured put on RYTM is the cash-secured put strategy applied to RYTM (stock). The strategy is structurally neutral to slightly bullish: A cash-secured put sells an out-of-the-money put while holding cash equal to the strike-times-100 obligation, keeping the premium when the underlying stays above the strike. With RYTM stock trading near $108.78, the strikes shown on this page are snapped to the nearest listed RYTM chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are RYTM cash-secured put max profit and max loss calculated?
- Max profit equals premium times 100; max loss equals strike minus premium times 100 (at zero, assuming assignment). Breakeven is strike minus premium. For the RYTM cash-secured put priced from the end-of-day chain at a 30-day expiry (ATM IV 55.00%), the computed maximum profit is $342.50 per contract and the computed maximum loss is -$10,156.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a RYTM cash-secured put?
- The breakeven for the RYTM cash-secured put priced on this page is roughly $101.58 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current RYTM market-implied 1-standard-deviation expected move is approximately 15.77%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a cash-secured put on RYTM?
- Cash-secured puts on RYTM earn premium while a trader waits to acquire RYTM stock at a target strike below the current quote; most attractive when IV is rich and the trader is comfortable owning RYTM.
- How does current RYTM implied volatility affect this cash-secured put?
- RYTM ATM IV is at 55.00% with IV rank near 15.91%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.